The 2008 US Food and Drug Administration (FDA) regulation requires to demonstrate in clinical trials of new antidiabetic drugs, that these drugs do not increase the risk of development of cardiovascular events as compared to existing drugs, after adjustment for major risk factors. It has been difficult to show superiority of newer drugs after adjustments for the major risk factors, and in fact, superiority could not be demonstrated in the initial three trials of DPP-4 inhibitors [1] [2] [3] . Therefore, it came as an unexpected surprise that the SGLT2 inhibitor empagliflozin showed superiority in the EMPA-REG OUTCOME study [4] . Thereafter, superiority was again demonstrated in one study of SGLT2 inhibitor, CANVAS [5] , two studies of GLP-1 receptor agonists, LEADER [6] , and , but not in another two studies of GLP-1 receptor agonists, ELIXA [8] , and EXCEL [9] .
. Therefore, it came as an unexpected surprise that the SGLT2 inhibitor empagliflozin showed superiority in the EMPA-REG OUTCOME study [4] . Thereafter, superiority was again demonstrated in one study of SGLT2 inhibitor, CANVAS [5] , two studies of GLP-1 receptor agonists, LEADER [6] , and SUSTAIN-6 [7] , but not in another two studies of GLP-1 receptor agonists, ELIXA [8] , and EXCEL [9] . Various hypotheses have been proposed in regard to factors influencing the demonstration of superiority, but there is no widely accepted theory. It has been suggested that differences in the patients' background characteristics may be a factor. It is also possible that the incidence of cardiovascular events is not sufficiently high in studies with a short study period, and that there is a bias towards patients with slightly higher risk being in the active drug group.
We focused on weight reduction, because weight gain is a risk factor for cardiovascular diseases, independent of disordered glucose metabolism, elevated blood pressure, and abnormal lipid profile [10] . We examined the correlations between the body weight changes and hazard ratios before and after treatment in eight studies [1] [2] [4] [5] [6] [7] [8] [9] . In SUSTAIN-6 [7] , since the analysis was carried out with semaglutide 0.5 mg and 1 mg treatment respectively, both were adopted. The TECOS study [3] was excluded, as there were no data on the body weight changes in this study.
As shown in the Figure 1 [1-9 ], there was a strong correlation between weight reduction and reduction in the hazard ratio in all trials (R 2 = 0.88, F = 51.6, P =1.8 × 10 -4 , n = 9). These results suggest that novel antidiabetic drugs that decrease the body weight also suppress cardiovascular events. It should be noted in interpreting this result that these trials were performed on patients at higher risk of cardiovascular events, such as patients with relatively advanced disease, elderly patients, and patients with some degree of renal impairment. Therefore, patients with low cardiovascular risks may have different results. Weight reduction results in various metabolic improvements, through reduction in the visceral fat area. It has been reported that liraglutide and SGLT2 inhibitors reduce the visceral fat area, which has been shown to be associated with cardiovascular diseases [11] .
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